OTCMKTS:RGRXRegeneRx Biopharmaceuticals Stock Price, Forecast & News

$0.34

+0.05 (+15.52 %)

(As of 06/1/2020 04:00 PM ET)

Add

Compare

Today's Range

$0.24

Now: $0.34▼

$0.35

50-Day Range

$0.21

MA: $0.26▼

$0.30

52-Week Range

$0.10

Now: $0.34▼

$0.35

Volume627,467 shs

Average Volume80,200 shs

Market Capitalization$44.70 million

P/E RatioN/A

Dividend YieldN/A

Beta0.81

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, Thymosin beta 4 (Tß4), for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for dermal wounds and reduction of scar tissue. It also evaluates the commercial development of peptide fragments and derivatives of Tß4 for potential cosmeceutical and other personal care uses. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was founded in 1982 and is headquartered in Rockville, Maryland.

Beat the Market (BTM) Rank^™

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for RegeneRx Biopharmaceuticals.

2.8 Community Rank

Outperform Votes
RegeneRx Biopharmaceuticals has received 102 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
RegeneRx Biopharmaceuticals has received 78 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
RegeneRx Biopharmaceuticals has received 56.67% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about RegeneRx Biopharmaceuticals and other stocks. Vote “Outperform” if you believe RGRX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RGRX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
RegeneRx Biopharmaceuticals does not currently pay a dividend.
Dividend Growth
RegeneRx Biopharmaceuticals does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, RegeneRx Biopharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 10.90% of the stock of RegeneRx Biopharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 0.19% of the stock of RegeneRx Biopharmaceuticals is held by institutions.

0.0 Earnings and Valuation

Overall Beat the Market Rank^™

0.56 out of 5 stars

Industry, Sector and Symbol

Stock Exchange OTCMKTS

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolOTCMKTS:RGRX

Previous SymbolOTC:RGRX

CUSIPN/A

CIK707511

Webwww.regenerx.com

Phone301-208-9191

Debt

Debt-to-Equity RatioN/A

Current Ratio2.33

Quick Ratio2.33

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$80,000.00

Price / Sales558.79

Cash FlowN/A

Price / Cash FlowN/A

Book Value($0.02) per share

Price / Book-16.75

Profitability

EPS (Most Recent Fiscal Year)N/A

Net Income$-1,400,000.00

Net Margins-1,910.16%

Return on EquityN/A

Return on Assets-161.30%

Miscellaneous

Employees3

Outstanding Shares133,442,000

Market Cap$44.70 million

Next Earnings Date6/3/2020 (Estimated)

OptionableNot Optionable

Receive RGRX News and Ratings via Email

Sign-up to receive the latest news and ratings for RGRX and its competitors with MarketBeat's FREE daily newsletter.

RegeneRx Biopharmaceuticals (OTCMKTS:RGRX) Frequently Asked Questions

How has RegeneRx Biopharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

RegeneRx Biopharmaceuticals' stock was trading at $0.2049 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, RGRX shares have increased by 63.5% and is now trading at $0.3350. View which stocks have been most impacted by Coronavirus.

When is RegeneRx Biopharmaceuticals' next earnings date?

RegeneRx Biopharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, June 3rd 2020. View our earnings forecast for RegeneRx Biopharmaceuticals.

Has RegeneRx Biopharmaceuticals been receiving favorable news coverage?

Headlines about RGRX stock have been trending very positive recently, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. RegeneRx Biopharmaceuticals earned a news impact score of 3.5 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutRegeneRx Biopharmaceuticals.

Who are some of RegeneRx Biopharmaceuticals' key competitors?

Some companies that are related to RegeneRx Biopharmaceuticals include Immunic (IMUX), Arbutus Biopharma (ABUS), Rockwell Medical (RMTI), Aldeyra Therapeutics (ALDX), BIOFRONTERA AG/ADR (BFRA), Sierra Oncology (SRRA), Minerva Neurosciences (NERV), Endonovo Therapeutics (ENDV), Conatus Pharmaceuticals (CNAT), Humanigen (HGEN), Evelo Biosciences (EVLO), Trevena (TRVN), Harrow Health (HROW), Zynerba Pharmaceuticals (ZYNE) and Theratechnologies (THTX). View all competitors.

What other stocks do shareholders of RegeneRx Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other RegeneRx Biopharmaceuticals investors own include Inpixon (INPX), Biocept (BIOC), Pharmacyte Biotech (PMCB), SANUWAVE Health (SNWV), Sierra Oncology (SRRA), Ampliphi Biosciences (APHB), AVEO Pharmaceuticals (AVEO), Biopharmx (BPMX), Co-Diagnostics (CODX) and Cytori Therapeutics (CYTX).

Who are RegeneRx Biopharmaceuticals' key executives?

RegeneRx Biopharmaceuticals' management team includes the following people:

Dr. Allan L. Goldstein, Founder, Chairman, Chief Scientific Officer & Chairman of Scientific Advisor Board (Age 81)
Mr. J. J. Finkelstein, Pres, CEO & Director (Age 67)
Mr. Dane R. Saglio, Chief Financial Officer (Age 61)
Dr. Nabila A. Turjman Ph.D., Exec. Director of Regulatory Affairs

What is RegeneRx Biopharmaceuticals' stock symbol?

RegeneRx Biopharmaceuticals trades on the OTCMKTS under the ticker symbol "RGRX."

How do I buy shares of RegeneRx Biopharmaceuticals?

Shares of RGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is RegeneRx Biopharmaceuticals' stock price today?

One share of RGRX stock can currently be purchased for approximately $0.34.

How big of a company is RegeneRx Biopharmaceuticals?

RegeneRx Biopharmaceuticals has a market capitalization of $44.70 million and generates $80,000.00 in revenue each year. RegeneRx Biopharmaceuticals employs 3 workers across the globe.

What is RegeneRx Biopharmaceuticals' official website?

The official website for RegeneRx Biopharmaceuticals is www.regenerx.com.

How can I contact RegeneRx Biopharmaceuticals?

RegeneRx Biopharmaceuticals' mailing address is 15245 SHADY GROVE ROAD SUITE 470, ROCKVILLE MD, 20850. The biopharmaceutical company can be reached via phone at 301-208-9191 or via email at [email protected]

This page was last updated on 6/2/2020 by MarketBeat.com Staff

OTCMKTS:RGRXRegeneRx Biopharmaceuticals Stock Price, Forecast & News

Adding